Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | RHEB | Q15382 | 4/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811732 | 1.00 | AHR (0.42) | AHRHRH4NOS1METAP2DYRK1A | |
| SCHEMBL5100201 | 0.85 | CYP19A1 (0.47) | AHRHRH4NOS1METAP2RHEB | |
| SCHEMBL17179281 | 0.84 | AHR (0.45) | AHRHRH4NOS1METAP2DYRK1A | |
| SCHEMBL30920844 | 0.81 | LOXL2 (0.58) | AHRHRH4NOS1METAP2DYRK1A | |
| SCHEMBL28748192 | 0.81 | AHR (0.42) | AHRHRH4NOS1METAP2DYRK1A | |
| SCHEMBL22529408 | 0.81 | LOXL2 (0.58) | AHRHRH4NOS1METAP2DYRK1A | |
| SCHEMBL8309165 | 0.81 | AHR (0.42) | AHRHRH4NOS1METAP2DYRK1A | |
| SCHEMBL5694475 | 0.79 | GPR17 (0.44) | HRH4 | |
| SCHEMBL17433389 | 0.78 | CYP19A1 (0.45) | AHRNOS1METAP2DYRK1ACYP2A6 | |
| SCHEMBL20544623 | 0.78 | GRIN2D (0.43) | AHRHRH4NOS1METAP2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-02 | — | — | US | disclosed |
| WO-2024056099-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京华益健康药物研究中心 | 2024-03-21 | — | — | WO | disclosed |
| CN-117720533-A | MetTL3 inhibitor compound and pharmaceutical composition and application thereof | 北京华益健康药物研究中心 | 2024-03-19 | — | — | CN | disclosed |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| CN-113498342-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2021-10-12 | — | — | CN | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
| EP-3421465-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2019-01-02 | — | — | EP | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2750504-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8697700-B2 | Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| WO-2013033258-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012088038-A2 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088038-A2 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157469-A1 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157469-A1 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157469-A1 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | AHR 3197/4885HRH4 4227/4885NOS1 4663/4885 |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | AHR 4210/4885HRH4 2159/4885NOS1 1813/4885 |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | AHR 3197/4885HRH4 4227/4885NOS1 4663/4885 |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | AHR 4708/4885HRH4 3795/4885NOS1 1949/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | AHR 4210/4885HRH4 2159/4885NOS1 1813/4885 |
| US-20120157469-A1 | PIPERAZINONE-SUBSTITUTED TETRAHYDRO-CARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | MCHR1, MCHR2, MC1R | AHR 63/4885HRH4 53/4885NOS1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.